Schlitt H J, Loss M, Scherer M N, Becker T, Jauch K-W, Nashan B, Schmidt H, Settmacher U, Rogiers X, Neuhaus P, Strassburg C
Klinik und Poliklinik für Chirurgie, Universitätsklinikum Regensburg.
Z Gastroenterol. 2011 Jan;49(1):30-8. doi: 10.1055/s-0029-1245946. Epub 2011 Jan 10.
Liver transplantation represents a successful and well-established therapeutic concept for patients with advanced liver diseases. Organ donor shortage continues to pose a significant problem. To ensure fair and transparent allocation of too few post-mortem grafts, the model of end-stage liver disease (MELD)-based allocation was implemented in December 2006. This has decreased waiting list mortality from 20 to 10 % but at the same time has reduced post OLT survival (1-year survival from almost 90% to below 80%), which is largely due to patients with a labMELD score > 30. Following MELD introduction the regular allocation threshold has increased from a matchMELD of initially 25 to meanwhile 34. At the same time the quality of donor organs has seen a continuous deterioration over the last 10 - 15 years: 63% of organs are "suboptimal" with a donor risk index of > 1.5. Moreover, the numbers of living-related liver transplantations have decreased. In Germany incentives for transplant centres are inappropriate: patients with decompensated cirrhosis, high MELD scores and high post-transplant mortality as well as marginal liver grafts are accepted for transplantation without the necessary consideration of outcomes, and against a background of the still absent publication and transparency of outcome results. The outlined development calls for measures for improvement: (i) the increase of donor grafts (e. g., living donation, opt-out solutions, non-heart beating donors), (ii) the elimination of inappropriate incentives for transplant centres, (iii) changes of allocation guidelines, that take the current situation and suboptimal donor grafts into account, and (iv) the systematic and complete collection of transplant-related data in order to allow for the development of improved prognostic scores.
肝移植是晚期肝病患者一种成功且成熟的治疗理念。器官供体短缺仍然是一个重大问题。为确保对数量稀少的尸检移植物进行公平、透明的分配,2006年12月实施了基于终末期肝病模型(MELD)的分配方式。这使等待名单上的死亡率从20%降至10%,但同时也降低了肝移植术后的生存率(1年生存率从近90%降至80%以下),这主要是由于实验室MELD评分>30的患者。引入MELD后,常规分配阈值从最初的匹配MELD 25增加到目前的34。与此同时,在过去10 - 15年中,供体器官质量持续下降:63%的器官“次优”,供体风险指数>1.5。此外,亲属活体肝移植的数量也有所减少。在德国,对移植中心的激励措施并不恰当:失代偿期肝硬化、MELD评分高且移植后死亡率高的患者以及边缘性肝移植物在未充分考虑结果的情况下被接受进行移植,而且在结果仍未公布且缺乏透明度的背景下也是如此。上述发展情况需要采取改进措施:(i)增加供体移植物(例如,活体捐赠、选择退出方案、非心脏跳动供体),(ii)消除对移植中心不恰当的激励措施,(iii)改变分配指南,使其考虑到当前情况和次优供体移植物,(iv)系统、完整地收集移植相关数据,以便制定改进的预后评分。